SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CEO Jurgi Camblong sold 50,069 shares of the firm's stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20. Following the completion of the transaction, the chief executive officer directly owned 3,601,493 shares in the company, valued at $20,888,659.40. This represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jurgi Camblong also recently made the following trade(s):
- On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $7,826.10.
- On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total value of $44,540.00.
- On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total value of $23,372.06.
- On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.00, for a total value of $87,365.00.
- On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total value of $213,919.84.
- On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total value of $20,939.24.
- On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.72, for a total value of $57,735.04.
- On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,243.00.
- On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total value of $13,552.00.
- On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.86, for a total value of $12,150.00.
SOPHiA GENETICS Trading Up 4.0%
Shares of SOPH opened at $5.98 on Tuesday. SOPHiA GENETICS SA has a 52-week low of $2.81 and a 52-week high of $6.00. The stock has a market cap of $501.66 million, a PE ratio of -11.50 and a beta of 0.98. The firm's fifty day moving average is $5.09 and its two-hundred day moving average is $4.93. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05.
SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). The business had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.
Analysts Set New Price Targets
A number of research firms have weighed in on SOPH. BTIG Research reissued a "buy" rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $7.50.
Read Our Latest Research Report on SOPH
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock valued at $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Federated Hermes Inc. increased its position in SOPHiA GENETICS by 16.4% during the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company's stock worth $682,000 after purchasing an additional 31,000 shares during the last quarter. Akre Capital Management LLC raised its stake in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the period. GSA Capital Partners LLP purchased a new position in SOPHiA GENETICS during the third quarter worth about $59,000. Finally, Dimensional Fund Advisors LP boosted its holdings in SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company's stock valued at $148,000 after purchasing an additional 6,205 shares during the last quarter. Hedge funds and other institutional investors own 31.59% of the company's stock.
SOPHiA GENETICS Company Profile
(
Get Free Report)
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
